Edgewise Therapeutics has dosed the first patient in EQUINOX-HFpEF, a Phase 2, randomized, double-blind, placebo-controlled trial of its oral cardiac sarcomere modulator EDG-15400 in adults aged 30 to 84 with symptomatic HFpEF and left ventricular ejection fraction of at least 50%. With first patient…
Edgewise Therapeutics (EWTX) has attracted considerable investor interest in the upcoming phase 3 design for '7500 in hypertrophic cardiomyopathy, representing an opportunity to h... Oops, something went wrong Edgewise Therapeutics' Investors Focused on Upcoming Phase 3 Design for '7500 in Hypertrophic Cardiomyopathy, RBC Says Edgewise…
2026-10-27. The following slide deck was published by Tango Therapeutics, Inc. in conjunction with this event.
Financing co-led by Novo Holdings and the Ljungström family office, with participation from the originator Helsinn, existing investors Pureos Biov... AnaCardio raises €62.5 million Series B financing to advance transformational novel therapy in heart failure towards Phase 3 readiness - Financing co-led by…
Dr. Marty Makary, the commissioner of the Food and Drug Administration, resigned on Tuesday, according to multiple media reports citing administ... FDA Commissioner Marty Makary resigns Dr. Marty Makary, the commissioner of the Food and Drug Administration, resigned on Tuesday,…
Xencor reports promising early kidney cancer drug data, with XmAb819 shrinking tumors in 45.5% of patients. Ridofranz/iStock via Getty Images Xencor (XNCR) reported encouraging results from an early-stage clinical trial of its experimental kidney cancer drug XmAb819, with tumors shrinking in nearly…
A 2026 narrative review finds that recombinant human B-type natriuretic peptide rapidly improves hemodynamic and renal measures in acute heart failure and myocardial infarction, while durable clinical benefits remain uncertain. One study found contrast-induced nephropathy in 13.5% of rhBNP recipients versus 24.0% of…
Scientists have uncovered new details about how pancreatic cancer constantly changes its genetic makeup, allowing it to become more aggressive, spread throughout the body, and resist treatment. By examining nearly half a million individual cancer cells, researchers identified genetic changes…
2026-10-24. The following slide deck was published by Lexeo Therapeutics, Inc. in conjunction with this event.
Hogan Lovells Cadwalader has hired a former U.S. Food and Drug Administration leader, who has more than 35 years of experience at the agency and worked as chief counsel, as a new member of its Washington, D.C., office, according to a Wednesday announcement.
How the FDA is run: its commissioners, Vinay Prasad and CBER, drug-center chiefs, priority vouchers, staff cuts and changes to drug review.
An article joins this feed when it matches these terms. Each one is also a search of its own.